Cat. No. ARG0145
Ubd Knockout B16-F10 is a CRISPR/Cas9-engineered mouse melanoma cell line with disruption of Ubd, which encodes the ubiquitin-like modifier FAT10. In the aggressive, highly metastatic B16-F10 background, this model supports studies of melanoma progression, tumor-immune interactions, and inflammation-associated cancer biology. Ubd/FAT10 is induced downstream of TNF-alpha and IFN-gamma via NF-kappaB and STAT1, and functions with UBA6, USE1/UBE2Z, NUB1, and the proteasome to regulate substrate turnover and inflammatory responses. The cell line is suitable for cytokine stimulation studies, western blotting, RT-qPCR, RNA-seq, proteasome assays, migration/invasion assays, and syngeneic tumor studies.
| Host Cell | B16-F10 |
| Morphology | Epithelial-like |
| Age | Unknown |
| Gene Name | Ubd |
| Gene Identifier | NCBI Gene ID 24108 |
| Temperature | 37°C |
| Atmosphere | 5% CO₂ |
| Sterility testing | Daily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination. |
| Mycoplasma testing | Negative for mycoplasma through PCR analysis |
| Pathogens | Cells tested negative for HIV-1, HBV, and HCV. |
Intended Use: This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.
Disclaimer: Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.
By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use.
This product is provided "AS IS". For Research Use Only. Not for human or animal therapeutic use.
The Ubd Knockout B16-F10 Cell Line is a CRISPR/Cas9-engineered mouse melanoma model in which the Ubd gene has been disrupted to eliminate functional Ubd/FAT10 expression. This stable edited cell line is generated in the B16-F10 background, a tumorigenic melanocytic cell model broadly used for mechanistic studies of melanoma biology. By combining targeted gene knockout with an aggressive metastatic melanoma host line, this product provides a tractable in vitro system for investigating Ubd-dependent effects on inflammatory signaling, proteasome-linked protein turnover, and tumor-associated cellular behavior.
B16-F10 is a murine melanoma subline derived from C57BL/6 mouse melanoma and is extensively used in syngeneic oncology and immuno-oncology research because of its robust tumor-forming capacity and high metastatic potential. The line is widely applied to studies of melanoma progression, invasion, dissemination, and tumor-immune interactions in both cell culture and in vivo settings. Its established use in metastasis-related phenotyping and cytokine-response experiments makes it a relevant host background for interrogating genes that connect inflammatory cues to tumor cell state, proteostasis, and immune regulation.
Ubd encodes ubiquitin D, also known as FAT10, a ubiquitin-like modifier induced predominantly by proinflammatory cytokines. Ubd expression is strongly regulated downstream of TNF-alpha and IFN-gamma signaling through NF-kappaB- and STAT1-associated transcriptional programs, with representative pathway components including TNFRSF1A, IFNGR1, RELA, and STAT1. At the protein level, FAT10 is activated by UBA6 and conjugated by USE1/UBE2Z to substrate proteins. FAT10ylated substrates can be recognized in association with NUB1 and targeted toward 26S proteasome-dependent degradation, while additional interactions with factors such as MAD2L1 and HDAC6 link Ubd to broader control of inflammatory stress responses, cell survival output, and immune-regulatory signaling. In this context, Ubd functions at the intersection of ubiquitin-like protein conjugation, antigen processing, proteasomal degradation, and cytokine-driven transcriptional remodeling.
Loss of Ubd in B16-F10 therefore provides a useful model for dissecting how FAT10-dependent proteostasis contributes to melanoma-associated inflammatory adaptation and tumor-immune crosstalk. In an aggressive melanoma background, Ubd knockout can support analyses of pathway dependency downstream of TNF-alpha or IFN-gamma stimulation, changes in proteasomal degradation output, and alterations in inflammatory gene expression programs relevant to tumor progression, immune evasion, and metastasis-associated phenotypes.
This cell line is suitable for western blotting, RT-qPCR, and RNA-seq studies of cytokine-inducible transcriptional responses; immunofluorescence and flow cytometry analyses of phenotype and immune-related markers; co-immunoprecipitation and FAT10-conjugate assays to examine UBA6-USE1/UBE2Z pathway function; and proteasome activity assays to evaluate degradation dependence. It can also be applied in phospho-signaling studies following TNF-alpha or IFN-gamma treatment, apoptosis assays, migration and invasion assays, and syngeneic in vivo tumor experiments designed to compare tumor growth, metastatic behavior, and tumor-immune interactions between Ubd-deficient and control melanoma cells. Researchers may contact Ascent Research for additional technical information, product details, or related gene-edited cell models.
